Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo Controlled, Withdrawal Study of Flare Prevention of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations
Conditions
Interventions
canakinumab
placebo
Locations
73
United States
Arkansas Children's Hospital Research Inst
Little Rock, Arkansas, United States
Children's National Medical Center
Washington D.C., District of Columbia, United States
University of Chicago Medical Center
Chicago, Illinois, United States
University of Louisville
Louisville, Kentucky, United States
New England Medical Center - Department of Allergy
Boston, Massachusetts, United States
Tufts Medical Center
Boston, Massachusetts, United States
Start Date
July 1, 2009
Primary Completion Date
September 1, 2011
Completion Date
September 1, 2011
Last Updated
October 16, 2012
Lead Sponsor
Novartis Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions